Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of

GlobeNewswireJun 20 19:30

Anavex Life Sciences(AVXL.US) Director Buys US$10,319.4 in Common Stock

$Anavex Life Sciences(AVXL.US)$ Director Donhauser Peter D.O. purchased 2,835 shares of common stock on Jun 14, 2024 at an average price of $3.64 for a total value of $10,319.4.Source: Announcement Wh

Futu NewsJun 17 20:13

H.C. Wainwright Maintains Anavex Life Sciences(AVXL.US) With Buy Rating, Maintains Target Price $40

H.C. Wainwright analyst Ram Selvaraju maintains $Anavex Life Sciences(AVXL.US)$ with a buy rating, and maintains the target price at $40.According to TipRanks data, the analyst has a success rate of 3

Futu NewsJun 11 18:31 · Ratings

Lilly's Donanemeb, Remternetug Set to Dominate Alzheimer's Treatment by 2030

Seeking AlphaJun 9 02:00

GSK, Boston Beer And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 0.5% on Monday.Shares of GSK plc (NYSE:GSK) fell sharply in today's pre-market trading after the company said it will

BenzingaJun 3 20:13

Anavex Life Sciences Corp.'s (NASDAQ:AVXL) 14% Loss Last Week Hit Both Individual Investors Who Own 59% as Well as Institutions

Key Insights Anavex Life Sciences' significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public A total of 25 investors have a majorit

Simply Wall StMay 30 22:38